POM-V Prescription Required Companion Animal

Metrocare Flavour 250 mg Tablets for Dogs and Cats

Active ingredient: Metronidazole

Form

Tablet

Species

Cats Dogs

Manufacturer

Ecuphar NV

VMD MA No.

32742/4016

What it's used for

spp. (i.e. C. perfringens or ). Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteria (e.g. C...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Metronidazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Metrocare Flavour 250 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

spp. (i.e. C. perfringens or ).
Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by
obligate anaerobic bacteria (e.g. Clostridia spp.) susceptible to metronidazole.

The recommended dose is 50 mg metronidazole per kg bodyweight per day, for
5-7 days. The daily dose may be divided equally for twice daily administration
(i.e. 25 mg/kg bodyweight twice daily).
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Bodyweight
Metrocare 250 mg
Tablets (daily
dose)
or
Metrocare 500 mg
Tablets (daily dose)
1.25 kg¼ 2.5 kg½ ¼ 3.75 kg¾ 5 kg1 ½ 7.5 kg1 ½¾ 10 kg2 1 15 kg3 1 ½ 20 kg4 225 kg2 ½ 30 kg 3 35 kg3 ½ 40 kg 4
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.
AN: 01292/2024 & 01293/2024
Halves: press down with your thumbs or fingers on both sides of the tablet.
Quarters: press down with your thumb or a finger in the middle of the tablet.
The remaining portion(s) should be given at the next administration(s).

Do not use in cases of hepatic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
AN: 01292/2024 & 01293/2024

Dogs and cats:
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Vomiting
Hepatotoxicity
Neutropenia
Neurological signs
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
AN: 01292/2024 & 01293/2024
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

None.

Special precautions for safe use in the target species
Due to the likely variability (time, geographical) in the occurrence of metronidazole
resistant bacteria, bacteriological sampling and susceptibility testing are
recommended.
Whenever possible, the veterinary medicinal product should only be used based on
susceptibility testing.
Official, national and regional antimicrobial policies should be taken into account
when the veterinary medicinal product is used.
In very rare cases, neurological signs may occur especially after prolonged treatment
with metronidazole.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Metronidazole has confirmed mutagenic and genotoxic properties in laboratory
animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory
animals and has possible carcinogenic effects in humans. However, there is
inadequate evidence in humans for the carcinogenicity of metronidazole.
Metronidazole may be harmful for the unborn child.
Personal protective equipment consisting of impervious gloves should be worn when
handling the veterinary medicinal product.
To avoid accidental ingestion, particularly by a child, unused part-tablets should be
returned to the open blister space, inserted back into the outer packaging and kept in
a safe place out of the sight and reach of children. In case of accidental ingestion,
seek medical advice immediately and show the package leaflet or the label to the
physician. Wash hands thoroughly after handling the tablets.
Metronidazole may cause hypersensitivity reactions. People with known
hypersensitivity to metronidazole should avoid contact with the veterinary medicinal
product.
Special precaution for the protection of the environment:
Not applicable.

Metronidazole may have an inhibitory effect on the degradation of other drugs in the
liver, such as phenytoin, cyclosporine and warfarin.
Cimetidine may decrease the hepatic metabolism of metronidazole resulting in
increased serum concentration of metronidazole.
Phenobarbital may increase hepatic metabolism of metronidazole resulting in
decreased serum concentration of metronidazole.

Return any divided tablet to the blister and store protected from light.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.